Activate Now
 
ProHealth fibromyalgia Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

The Legs of Fibromyalgia and Myofascial Pain

Our Mind Wants What Our Body Can't Produce

Relief for Dry, Itchy Skin Caused by Fibromyalgia

Reversing Alzheimer’s: What Could it Mean for Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia?

VIDEO: Fibromyalgia Warnings

Recovering from Chronic Fatigue Syndrome and Fibromyalgia - The Lerner Way

4 Simple Ways to Shift into Positivity

3 Reasons Why Fibromyalgia May Affect Women More Than Men

VIDEO: "I Live with Pain Everyday" (Stories of Fibromyalgia)

Did MitoQ Mend Us? A Fibromyalgia and Chronic Fatigue Syndrome (ME/CFS) CoQ10 Trial

 
Print Page
Email Article

GLYX-13 looks like lucky number for depression prone

  [ 9 votes ]   [ Discuss This Article ]
www.ProHealth.com • December 9, 2012


Effect size within 24 hours after a single dose was nearly double the effect size seen with most other antidepressant drugs after four to six weeks of repeated dosing.

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested in a 12-site phase IIa trial on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety, and produce positive effects that last for about seven days from a single dose. (A 20-site phase IIb trial now underway is studying the effect of repeated doses.)

The novel therapeutic targets brain receptors responsible for learning and memory - a very different approach from existing antidepressants. The new drug and others like it also could be helpful in treating other neurological conditions, including schizophrenia, bipolar disorder, anxiety and Alzheimer’s disease.

The compound, called GLYX-13, is the result of more than two decades of work by Joseph Moskal, PhD, research professor of biomedical engineering at Northwestern. On Dec 3, the journal Neuropsychopharmacology published a paper describing some of the research underlying the clinical development of GLYX-13. And on Dec 6 Prof Moskal presented the results of the recent trial to members of the American College of Neuropsychopharmacology at their annual meeting in Hollywood, FL.

“Our study showed that this compound is capable of eliciting a robust and rapid antidepressant effect without the typical side effects seen with other drugs that also modulate the NMDA receptor,” says Dr. Moskal, who is founder and chief scientific officer of the Evanston, IL-based biotechnology company Naurex Inc., which conducted the clinical study. (Northwestern has granted to Naurex exclusive licensing of the intellectual property rights related to the therapeutics Dr. Moskal developed while at the University, and has a small equity position in Naurex.)

GLYX-13 works by modulating the NMDA (N-methyl-D-aspartate) receptor in the brain, as do current NMDA receptor antagonists such as ketamine, but GLYX-13 does not have their serious and limiting side effects, such as hallucinations and schizophrenia-like effects. (An antagonist is a substance that inhibits the physiological action of another.)

Dr. Moskal and his team have figured out a new way to target the NMDA receptors that maintains the positive antidepressant properties while eliminating the negative side effects.

In clinical trials administered at 12 sites across the country, a single dose of GLYX-13 resulted in significant reductions in depression symptoms among subjects who had shown little improvement with previous drugs. (Subjects had failed treatment with one or more antidepressant agents.)

The positive effects of GLYX-13 were evident within 24 hours and lasted an average of seven days.

The effect size, a measure of the magnitude of the drug’s antidepressant efficacy, at both these times after a single dose was nearly double the effect size seen with most other antidepressant drugs after four to six weeks of repeated dosing.

Side effects of GLYX-13 were mild to moderate and were consistent with those observed in subjects receiving a placebo.

GLYX-13 is a four-amino acid peptide that modulates one of a large family of glutamate receptors, the NMDA (N-methyl-D-aspartate) receptor, in the brain. NMDA receptors play a key role in regulating synaptic plasticity - the quality of the connection between neurons - and thus are important in regulating learning and memory functions.

GLYX-13 is currently administered intravenously, but Naurex is now working on an oral drug with similar properties and potential, Dr. Moskal says.

Further, he says, it is his hope that these positive GLYX-13 results and the research efforts of his team and colleagues will help shepherd in more research and grant support for studying the role of the glutamate-mediated processes in neuropsychiatric disorders.

“While the results we are seeing with GLYX-13 are very encouraging, I believe the most important research is yet to come,” he adds. “We have only scratched the surface of the therapeutic potential of the glutamatergic system.”

GLYX-13 currently is undergoing a phase IIb clinical trial at 20 sites across the United States. This trial is evaluating repeated doses of the drug.

__

Source: Based on Northwestern University press release by Megan Fellman with contributions by Sarah Ostman, Dec 6, 2012




Post a Comment

Featured Products From the ProHealth Store
Fibro Freedom™ B-12 Extreme™ FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Fibro Freedom™ Fibro Freedom™
Soothes, Strengthens & Revitalizes
Guaifenesin FA™ Guaifenesin FA™
Helps the Body Eliminate Excess Calcium and Phosphates
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness

Natural Remedies

More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
Nutrients to Combat the Modern Stress Epidemic Nutrients to Combat the Modern Stress Epidemic
The Curcumin Revolution: 'Golden' Ticket to Better Health The Curcumin Revolution: 'Golden' Ticket to Better Health

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map